DURHAM — Durham-based KNOW Bio LLC has raised another $1.1 million in an equity offering, according to a recent filing with the Securities and Exchange Commission.
Formerly known as Novoclem Therapeutics, Inc., KNOW Bio, is a Research Triangle-based incubator for platform-based medical technology and biotechnology companies. After four filings since 2017, it has raised a total of around $13 million from 74 investors, according the document.
Among its subsidiaries is Vast Therapeutics, a pre-clinical stage pharmaceutical company for patients with respiratory diseases. It uses a nitric oxide technology which was developed with Dr. Mark Schoenfisch’s lab at UNC-Chapel Hill.
The filing comes as Vast announced it has completed its Series A financing with a single investor, Shinogi & Co., Ltd. of Japan.
Durham’s Vast Therapeutics gets Series A financing to fight superbugs
The investment provides Vast with funding to advance its “novel nitric oxide powder platform through pre-clinical testing and first-in-human clinical safety and efficacy trials during the next two years”.
